The Enhancing Oncology Model (EOM) is a voluntary, patient-centered healthcare payment model developed by the Centers for Medicare & Medicaid Services (CMS) to improve cancer care delivery and outcomes while reducing costs.
Sponsors considering using data from sensors and wearables in their clinical trials worry about three scenarios: collecting too little data, collecting too much data, and collecting bad data. Each outcome could likely impact their study or a portion of it with a significant waste of time, money, and patient goodwill.
Clinical Ink’s Chief Innovation Officer, Joan Severson, joined a group of panelists on The Real Chemistry podcast during this year’s SXSW to provide insight into how the use of innovative data sources for clinical trial recruitment has become increasingly important in recent years.
Analyzing data collected through our collaborative Watch-PD study, we demonstrated digital biomarkers could detect both the presence of Parkinson’s disease (PD) as well as response to treatment.
Caregivers play a critical role in oncology trials, providing support and assistance to patients who are dealing with physical, emotional, or cognitive challenges related to their illness and treatment. Caregivers are made up of a wide range of individuals including parents of minor children, adult children of parents, spouses or partners of participants, and home health aides.
We all benefit from many technological advances—from GPS to AI/ML to ChatGPT—without questioning exactly how they work. There’s no real need to understand what goes on “behind the curtain” or “under the hood.” The focus is on what is created over how output and results are created.
While ePRO technology is increasingly being used in clinical trials to streamline data collection, oncology trials present a unique set of challenges that can make implementing a successful ePRO solution difficult.
Business purchases are driven by a sticker price. Then there’s the true, all-inclusive cost that accumulates the soft costs, the downstream costs, and even the cost of unintended consequences. Savvy decision makers attempt to consider them all, but it usually isn’t an easy exercise.
There’s a single word that captures the spirit of business since the start of the pandemic: “direct.” Brands are adopting direct-to-consumer models wherever possible to trim time and costs from the distribution chain. And it’s not that different in the data world. “Direct” is the catchword of the day.
Imagine if someone were to give you hours more time in your day. Most people would gladly take it. In essence, that’s what eSource technology offers investigator sites — 30 percent more time to spend on patient care.
As Sponsors incorporate eSource technologies and decentralized data collection into their trials, barriers to patient participation and adherence are beginning to fall away.
When electronic data capture (EDC) systems came onto the clinical trial scene, no one expected them to…
Sales and Solutions
Direct 1.336.714.7402
Support
Toll-Free 1.800.301.5033
Direct 1.336.714.7402
Insert HTML text here.
